News | June 03, 2022
Lockwood acquires medical animation studio ‘Random42’ from Graphite Capital
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The StealthStation S8 and O-arm Surgical Navigation solution make a complex surgery seem more routine and free of any errors
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
The new wing will cater to all aspects of mother and child health by offering comprehensive, end to end services in radiology, diagnostics, obstetric surgeries and an exclusive gynaecology emergency section
Subscribe To Our Newsletter & Stay Updated
